

ANIKA THERAPEUTICS INC
Form 8-K
December 03, 2003

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

**PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): **December 2, 2003**

Anika Therapeutics, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Massachusetts

(State or Other Jurisdiction of
Incorporation or Organization)

000-21326

(Commission file
Number)

04-3145961

(I.R.S. Employer Identification
No.)

160 New Boston Street, Woburn, Massachusetts

(Address of Principal Executive Offices)

01801

(Zip Code)

Registrant's Telephone Number, Including Area Code: **(781) 932-6616**

Item 5: Other Events and Required FD Disclosure.

On December 2, 2003, Anika Therapeutics, Inc. issued a press release (Press Release) announcing that it had received an approvable letter from the U.S. Food and Drug Administration regarding its ORTHOVISC® osteoarthritis product. A copy of the Press Release is attached hereto as Exhibit 99.1 and incorporated herein by reference in its entirety.

Item 7: Financial Statements, Pro Forma Financial Information and Exhibits.

(c) Exhibits

Exhibit No.	Description
99.1	Press Release issued by Anika Therapeutics, Inc. on December 2, 2003

SIGNATURES

Edgar Filing: ANIKA THERAPEUTICS INC - Form 8-K

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ANIKA THERAPEUTICS, INC.

December 2, 2003

By: /s/ Charles H. Sherwood
Charles H. Sherwood, Ph.D.
Chief Executive Officer and President

3

Exhibit Index

Exhibit No.	Description
99.1	Press Release of Anika Therapeutics, Inc. dated December 2, 2003